SARS-CoV-2 infectivity is effectively treated and prevented using a combination of MEK and p38 inhibitors

Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/289248

COMPARTIR / EXPORTAR:

SHARE BASE	Comparte tu historia de Acceso Abierto
Visualizar otros formatos: MARC \| Dublin Core \| RDF \| ORE \| MODS \| METS \| DIDL \| DATACITE
Refman EndNote Bibtex RefWorks Excel CSV PDF DataCite Send via email

Título:	SARS-CoV-2 infectivity is effectively treated and prevented using a combination of MEK and p38 inhibitors
Autor:	Casar, Berta CSIC ORCID
Fecha de publicación:	5-oct-2022
Citación:	II Jornadas Científicas PTI+ Salud Global (2022)
Resumen:	The MEK inhibitors (MEKi) Trametinib/Selumetinib/Cobimetinib are FDA/EMA-approved drugs for metastatic melanoma treatment; whereas the p38 inhibitor Losmapimod is currently in phase II trials for chronic obstructive pulmonary disease. Herein, we show a drug class-effect MEK and p38 inhibitors in suppressing SARS-CoV-2- virus infection of human cells. We aim at establishing these MAPK inhibitors' potential as antivirals in comparison to the most effective therapeutics currently utilized in the clinic against COVID-19, namely: Hydroxychloroquine, the antiretroviral Remdesivir, and the IL6 inhibitor Tocilizumab.
Descripción:	Trabajo presentado en las II Jornadas Científicas PTI+ salud global, celebradas en Valencia (España) del 05 al 06 de octubre de 2022.
URI:	http://hdl.handle.net/10261/289248
Aparece en las colecciones:	(IBBTEC) Comunicaciones congresos (PTI Salud Global) Colección Especial COVID-19